Research shows XZ.700* could block tumor promoting effects of S. aureus on malignant T cells, potentially delaying tumor progression.
Findings strengthen potential of Micreos’ endolysin technology to address unmet patient needs in treating CTCL in the wake of devastating antimicrobial resistance.
Zug, Switzerland, 7th March 2023 – Micreos is pleased to share the positive results of an investigational study: Endolysin inhibits skin colonization by patient-derived Staphylococcus aureus and malignant T cell activation in cutaneous T cell lymphoma, published in the Journal of Investigative Dermatology, 2023 (https://doi.org/10.1016/j.jid.2023.01.039). The study, led by Prof Niels Ødum, University of Copenhagen’s Skin Immunology Research Centre, was undertaken to investigate the effect of endolysin (XZ.700*) on skin colonization, chemokine expression, proliferation of pathogenic S. aureus and possible tumor-blocking effects on malignant T cells.
Cutaneous T-cell lymphoma (CTCL) is a rare, debilitating form of skin cancer affecting T cells that are part of the immune system. S. aureus and staphylococcal enterotoxins (SE) have been suspected to fuel disease activity and cancer progression in CTCL through a direct stimulation of the malignant T cells1-3. It has a profound impact on patients’ quality of life due to its chronic nature and the fact that a considerable proportion of patients either have a poor response or no sustained response to current treatments4,5. CTCL is a rare disease with less than 200,000 patients in the US meaning that the indication qualifies for an Orphan Drug Designation6,7.
Niels Ødum, Professor at University of Copenhagen’s Skin Immunology Research Centre, who has been working with Micreos to validate the approach of endolysin treatment in CTCL from a pre-clinical perspective said, “The results of this study are significant as they show the endolysin XZ.700* has the potential to improve outcomes for patients by targeting bacteria that are associated with CTCL disease activity and progression. Treating S. aureus with antibiotics is discouraged due to the associated risk of antibiotic resistance induction. Thus, there is an important medical need for new, specific, anti-staphylococcal alternatives such as XZ.700* that show no signs of resistance induction. This study showed that the endolysin XZ.700* profoundly inhibited skin colonization by S. aureus of both healthy skin and lesional CTCL skin. Importantly, we saw that this endolysin killed S. aureus after the S. aureus colonization had been established. This suggests that XZ.700* has potential in both an acute treatment-setting and as a prophylactic treatment.”
XZ.700* has been developed by Micreos, a world-class endolysin platform company, as a topical treatment of the inflammatory skin symptoms associated with CTCL and for the reduction of disease activity in adult patients with CTCL. Studies have shown that aggressive antibiotic treatment inhibits proliferation of malignant T-cells and disease activity1. However, antibiotics are not a viable option for chronic use due to resistance development and the impact on the skin microbiome8. Research and development have been progressing swiftly and based on pre-clinical models Micreos has moved the development program from XZ.700* to the next generation endolysin namely, MEndoC.
“Micreos is committed to achieving a ‘medical paradigm shift’ in successfully treating life-threatening and disabling bacterial pathogen associated diseases where antibiotics cannot be used or are ineffective. XZ.700* was the first of many innovative endolysins in our development portfolio.” Said Matt Regan, CEO of Micreos. “Prof Ødum’s work has been incredibly important. Given the highly encouraging results, we are moving forward our research and development programme in CTCL with our ‘next generation’ endolysin MEndoC that has significantly higher intrinsic activity levels. This is extremely positive news as we move closer to our clinical trial program. We are working to make engineered endolysin-based treatments a clinical reality giving physicians the ability to specifically & selectively target harmful bacteria which play a significant role in diseases like CTCL, while preserving the rest of the Microbiome. This can provide an important & potentially viable solution to the global AMR crisis.”
Media Contact: Investor Contact:
Natalie Samuel Trine Ahlgreen
Phone: +44 7542 595192 Phone: +45 40450093
Micreos is a clinical-stage pharmaceutical biotech developing medicinal solutions to combat antimicrobial resistance and make a profound difference to humanity. With its unique capability in modular engineering to optimize enzyme therapeutics, Micreos is pioneering the development of antimicrobials that selectively kill only harmful bacteria whilst preserving the rest of the health-enhancing microbiome.
Micreos is focused on the challenges facing modern medicine in the 21st century by selecting and engineering biological alternatives to current antibiotics which are increasingly powerless to combat bacterial infections that play a significant role in disease, often beyond the primary infection. Current investigational treatments are being evaluated in three therapeutic areas that are caused or aggravated by pathogenic bacteria and where burgeoning antibiotic resistance is leaving patients with increasingly limited options: Cutaneous T-cell Lymphoma (CTCL), Atopic Dermatitis (AD) and Bacterial Bloodstream Infection (BBI).
Based on pre-clinical models and increased intrinsic activity, Micreos has moved the development program in CTCL from XZ.700 to the next generation endolysin, namely MEndoC.
Endolysins are small organic structures originally used by bacteria-killing viruses, called bacteriophages. Endolysins work by attaching themselves to the outside of the bacteria. Once attached they break down bonds within the bacterial cell wall causing the bacteria to burst and die. Both of these steps require structures that are unique to both the endolysin and the target bacteria meaning that endolysins only attack and kill one type of bacteria.
Micreos employs a unique science-driven approach to engineer endolysins and bacteriophages into targeted antibacterial treatments, leveraging the high potential of both technologies for its proprietary products. Its molecules selectively target harmful bacteria – including antibiotic resistant strains – which cause and exacerbate acute and chronic illnesses. The natural bacteria of the microbiome, beneficial for our health, remain unaffected. Due to the unique mode of action of endolysins, the emergence of resistance is extremely unlikely.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding expectations surrounding the potential of our product candidates, including our lead candidate XZ.700 (MEndoC) and expectations regarding our pipeline, including trial design, initiation of preclinical studies and advancement of multiple preclinical development programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future result. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
Since its founding in 2005, Micreos has become a world leading developer of endolysin and phage technology, enabling the targeted killing of only unwanted bacteria while protecting the rest of the Microbiome. This has the potential to play a significant role in addressing the impending antimicrobial resistance (AMR) issues.
The pharmaceutical business, that carries the Micreos name, is now an independent company that can focus wholeheartedly on engineered endolysin and engineered phage-based antimicrobials, initially focusing on Staphylococcus aureus (S. aureus) in oncology, dermatology, and bloodstream infections.
Matt Regan, CEO of Micreos, says: “The heritage of Micreos has enabled us to build a very solid pharmaceutical business model centered around a highly structured drug discovery and drug development approach focusing on three therapeutic areas – namely oncology, dermatology, and bloodstream infections. The impact of harmful bacteria on disease progression in chronic and acute settings and global concerns around antibiotic resistance leaves patients and clinicians with increasingly limited options. Our Micreos technology provides a potential novel approach to target both these issues in a highly sustainable way. Now it’s time to forge our own path forward, together with our investors and our scientific partners. It’s full steam ahead from here on.”
In parallel with the spin-off, a new leadership team has been assembled, bringing in decades of experience from the pharmaceutical industry. You can read more about the Micreos leadership team here
THE HAGUE, The Netherlands, October 25, 2022 – (BUSINESS WIRE)
Dutch/Swiss biotech company Micreos announced today it has secured its next funding round of €25 million in growth capital and for clinical development of its endolysin technology platform, set to replace antibiotics in many areas. This technology enables – for the first time – targeted killing of only the unwanted bacteria, regardless of resistance.
The funding comprises growth capital for Gladskin, the company’s specialized skincare brand, for people suffering from inflammatory skin conditions such as acne, eczema and rosacea. Last year Gladskin already helped hundreds of thousands of people in Europe and the USA, many of them experiencing a life-changing impact.
Proceeds are also earmarked for Micreos’ pharmaceutical program. This includes the clinical development of endolysins against staphylococci (including MRSA) for Bloodstream Infections, Atopic Dermatitis, Diabetic Foot Ulcers and Cutaneous T-cell Lymphoma, a type of skin cancer associated with the presence of S. aureus bacteria on the skin.
Over the past year Micreos separated its Pharmaceutical business from its ‘Over the Counter’ Consumer Health business. Micreos CEO Mark Offerhaus: “With this restructuring we align business and market requirements, enabling each business to pursue its own growth strategy. This is especially important for the pharmaceutical business, which is capital intensive and which we consider extremely promising. Direct investments in the Micreos Pharma, headed by Matt Regan, will now be possible.’’
Endolysins are naturally occurring enzymes that have the ability to target only harmful bacteria, while preserving the beneficial ones that form an important part of our natural defense, often referred to as our microbiome. Endolysins are safe and environmentally friendly. Because of their working mechanism, development of resistance is not expected and antibiotic resistance is not relevant.
Micreos develops targeted antibacterial solutions based on endolysin- and phage technology as a sustainable alternative for antibiotics. The group has pioneered the development of this technology and brought the world the first endolysin-based precision antibacterials.
The group’s head office is based in The Hague, NL. Micreos Pharmaceuticals has headquarters in Zug, CH, a Discovery and Technology Center in Wädenswil, CH, and a Development Team in Bilthoven, NL. Gladskin is based in the Netherlands, with offices in the USA, Germany, France and the UK. Micreos Food Safety is based in Wageningen, NL and markets FDA-and USDA-approved PhageGuard products against food pathogens such as Listeria, Salmonella and E. coli for food processing companies in the meat & poultry, fish, cheese and fresh produce industry. Micreos maintains a long-term collaboration with the Swiss Federal Technology Institute ETH in Zürich.
Maarten van Dun
Director Corporate Communication Micreos
Dr. Matthew Dunne, Dr. Samuel Kilcher and Dr. Anja Keller join us from the Swiss Federal Institute of Technology (ETH Zurich), with the goal of developing synthetic precision antimicrobials for medical indications across infectious and inflammatory diseases.
The new Division of Antimicrobial Vector Innovation builds on existing synthetic phage technology established at ETH and our own experience in developing and commercializing precision antimicrobials for many years.
Co-Directors Dr. Matthew Dunne and Dr. Samuel Kilcher bring with them extensive experience and knowledge within the fields of phage therapy, molecular microbiology, genetic engineering, and technology development.
If you want to learn more about the huge potential of synthetic phage technology in the quest for sustainable antimicrobial solutions, read this great article from ETH: https://www.sciencedirect.com/science/article/pii/S1879625721001607
We are very happy to have our new colleagues onboard as we continue the fight against bacterial infections and antimicrobial resistance!
In a new publication, the company’s flagship compound proves effective in targeting the harmful pathogen while preserving a healthy microbiome
Zug, Switzerland, 14 April 2022 — Micreos Pharmaceuticals today announces findings from a study proving the effectiveness of XZ.700, a novel antibacterial enzyme, in selectively targeting and killing the harmful Staphylococcus aureus bacterial pathogen while maintaining a healthy microbiome and preventing antimicrobial resistance (AMR). XZ.700 is the first of many innovative endolysins in the Micreos Pharmaceuticals portfolio and is critically important as the first molecule the company will bring to market. The findings were published in Antimicrobial Agents and Chemotherapy.
S.aureusis a pathogen associated with causing and aggravating a wide spectrum of conditions, ranging from mild disorders to life-threatening disease. These infections can be difficult to treat because S. aureus can hide in niches within the body, and it readily develops resistance to antibiotics. To date, there is no pharmaceutical treatment available that specifically targets S. aureus, thereby relieving symptoms while keeping the healthy skin microbiota intact.
XZ.700 is a novel antibacterial enzyme which effectively kills S. aureus without harming closely related and beneficial organisms, such as Staphylococcus epidermidis, which is part of the normal human skin microflora. Researchers from Micreos and ETH Zurich designed XZ.700 by combining elements from a bacteriophage endolysin and a S. aureus-specific bacteriocin, both agents that naturally target bacteria. They found that XZ.700 selectively removes S. aureus from a simplified skin microbiome and is effective against S. aureus on reconstituted human skin and in a mouse model of a S. aureus-induced skin infection. Importantly, no resistance emerged in S. aureus when it was repeatedly exposed to XZ.700 – a critical feature amidst the soaring AMR crisis.
“I am proud to see how developments at Micreos that are based on fundamental research conducted in our lab at ETH are now progressing into medical applications to help patients with inflammatory skin conditions,” said Professor Martin Loessner of ETH Zurich, a leading researcher and co-author of the paper.”
“XZ.700 forms one of the main building blocks of our endolysin portfolio and is the starting point for many more molecules to come,” said PD Dr. Mathias Schmelcher, Chief Scientific Officer at Micreos Pharmaceuticals, and co-author of the research. “With our technology, we have the possibility to selectively target the pathogen S. aureus while preserving a healthy skin microbiome. This could revolutionise the way we treat inflammatory skin disorders with an infectious component in the future.”
AMR is an issue of growing global importance which results in 750,000 deaths per year. It occurs when pathogens adapt so much so that the drugs used to treat infections become less effective. If not addressed, the spread of antibiotic-resistant pathogens could continue to rise, leading to highly dangerous superbugs. The number of annual global deaths from AMR is projected to increase to 10 million by 2050 unless alternatives to antibiotics are developed – which is more people than die globally of cancer today. Micreos Pharmaceuticals intends to play a very significant role in addressing AMR and the great unmet medical need for a safe alternative to antibiotics.
Micreos Pharmaceuticals develops new biological therapies based on the targeted killing of unwanted bacteria, which has potential in a broad range of applications. The company is viewed as a global leader in this field. Its proprietary endolysin technology has been created together with the Swiss Federal Institute of Technology, ETH in Zurich.
Micreos Pharmaceuticals is located in Zug, Switzerland and has a drug discovery / technology research centre in Zurich, Switzerland with a drug development and clinical operation in Bilthoven in the Netherlands.
Zug, Switzerland, 5-April 2022 — Micreos Pharmaceuticals today announces the expansion of its leadership team to include Trine Ahlgreen as Chief Business Officer and Carsten Edwards as Chief Development Officer. Their significant leadership experience within large, global pharmaceutical organisations will enable Micreos to accelerate the journey of developing viable alternatives to traditional antibiotics in select medical indications by leveraging proprietary endolysin technology, which selectively targets and kills harmful bacteria while preserving the rest of the microbiome.
The addition of Trine Ahlgreen and Carsten Edwards to the senior team represents an important step forward in building the strategic capabilities to make the right choices in the months and years ahead.
As Chief Business Officer, Trine Ahlgreen is responsible for building-out the pharmaceutical business strategy including commercial input into the development program and the selection & prioritisation of new indications where bacteria are the underlying pathogen. She will also be responsible for forging partnerships with pharma and diagnostic companies to design the go-to-market strategies and deliver solutions to improve patient standards-of-care. Trine has spent the last 20 years at Novo Nordisk in various geographies leading marketing and sales operations across the company’s portfolio.
Carsten Edwards brings 30 years of diverse experience in value, access, pricing, and health economics outcomes functions across companies including Novo Nordisk, AbbVie, and Bristol-Myers Squibb. Carsten has also worked in consultancy and is a recognised expert in drug development and the data packages required to secure global patient access. As Chief Development Officer, Carsten will lead Micreos Pharmaceuticals’ entire drug development programs, including pre-clinical, analytical methods development, API manufacturing, and drug formulation development, to optimise therapeutic effect and to maximise patient outcomes
“We are delighted to expand our senior team at this critical moment in the Micreos Pharmaceuticals’ journey and to attract people of the calibre of Carsten and Trine into our organisation. They are among the very best people in our industry,” said Matt Regan, CEO of Micreos Pharmaceuticals, who joined the company in October 2021. “Trine and Carsten bring significant pharmaceutical industry experience, success, and know-how that will help us to make the right choices in early drug discovery and in our pharmaceutical development programs to ensure that we are raising the standards of care for patients in our selected disease areas.”
Micreos Pharmaceuticals develops new biological therapies based on the targeted killing of unwanted bacteria, which has medical potential in a broad range of applications. The company is viewed as a global leader in this field. Its proprietary endolysin technology has been created together with the Swiss Federal Technology Institute, ETH in Zurich.
Micreos Pharmaceuticals is located in Zug, Switzerland and has a Drug discovery / Technology research centre in Zurich, Switzerland with a Drug development & Clinical operation in Bilthoven in the Netherlands.
AMR is an issue of growing global importance which results in 750,000 deaths per year. It occurs when pathogens adapt so that the drugs used to treat infections become less effective. If not addressed, the spread of antibiotic-resistant pathogens could continue to rise, leading to highly dangerous superbugs. The number of annual global deaths from AMR is projected to increase to 10 million by 2050 — which is more people than die globally of cancer today – unless successful alternatives to antibiotics are developed.
Micreos Pharmaceuticals intends to play a very significant role in addressing AMR and the great unmet medical need for a safe alternative to antibiotics.
The Hague, October 14, 2021 – Dutch biotechnology company Micreos has recruited Matt Regan as CEO of its new Pharmaceutical business that will be based in Switzerland. Following rapid growth, Micreos is preparing to spin-out its Pharmaceutical business into a separate company as per January 2022 to directly access the capital markets. This will help to fund pipeline development to progress its highly innovative, targeted antibacterial technology platform into pharmaceutical solutions that can improve patient care.
The Micreos endolysin technology enables selective killing of unwanted bacteria, regardless of resistance profiles. Its pharmaceutical lead compounds are XZ.700, which specifically kills Staphylococcus aureus, and SP.800, which kills all staphylococci.
XZ.700 is being studied in patients with Atopic Dermatitis via targeted elimination of S. aureus, while preserving the rest of the microbiome. Other XZ.700 indications being studied include Cutaneous T-cell lymphoma, a form of skin cancer associated with excessive skin-colonization of S. aureus and Diabetic Wound Infections. SP.800 will be developed as an intravenous solution for Bacteremia.
Matt joins Micreos with extensive biopharmaceutical experience from almost 3 decades working with Global healthcare leaders including Abbott, Novo Nordisk, and AbbVie. He has extensive experience across the entire value chain from Manufacturing to Commercial operations and has lived & worked in 7 different countries. Matt brings strategic & operational leadership experience to the company while also deeply understanding the needs of healthcare systems to address unmet medical needs. “I am greatly looking forward to joining the Micreos team and its many talented employees in this important mission of developing viable alternatives to traditional antibiotics. This is extremely important for patients – but also for healthcare systems around the world who are very concerned about Antimicrobial resistance.” comments Matt Regan.
“It’s fantastic to welcome Matt to Micreos. Matt shares our values and the determination to take our technology to the next level. Challenging the way chronic inflammation is currently treated, we aim to open up new ways to help millions of people around the world”, says Mark Offerhaus, founder and CEO of Micreos.
Micreos develops new biological therapies based on the targeted killing of only unwanted bacteria, which has the potential to replace antibiotics in a wide range of applications. The company is viewed as a global leader in this field. Its proprietary endolysin technology has been created together with the Swiss Federal Technology Institute, ETH in Zurich. Headquartered in The Hague, The Netherlands, Micreos runs its technology research center in Zurich, with development operations in The Netherlands and the USA. Under the Gladskin brand, Micreos has launched several OTC products for people with inflammatory skin conditions caused or aggravated by Staphylococcus aureus, including acne, eczema, and rosacea. Phageguard represents Micreos’s contribution to safer food production processes, based on targeted prevention of dangerous food pathogens such as Salmonella and Listeria.
For more information please contact: Melanie Stinn, Head of Corporate Communications (email@example.com) +49-151-2126-1437
THE HAGUE, The Netherlands, 30 September, 2021 – Dutch biotechnology company Micreos announced it has secured another €32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria. This funding round will help Micreos accelerate its clinical development programs for atopic dermatitis, diabetic (MRSA-)wounds and bloodstream infections, based on its pharmaceutical lead compounds, XZ.700 and SP.800.
In its search for solutions, Micreos’ researchers, in close collaboration with the Swiss Federal Technology Institute ETH Zurich, turned to nature’s own precision anti-bacterials, named endolysins. Unlike antibiotics, these highly specific enzymes have the ability to target only unwanted bacteria, while preserving the microbiome, comprising billions of ‘good’ bacteria, essential for our health. Endolysins are safe and environmentally friendly. Because of their working mechanism, development of resistance is not expected.
XZ.700 targets Staphylococcus aureus (S. aureus), including the antibiotic-resistant MRSA, while preserving Staphylococcus epidermidis, considered to be beneficial on the skin and conducive to wound healing. SP.800 targets all staphylococcal species. The XZ.700 and SP.800 clinical development programs includes the following indications:
Atopic Dermatitis: Micreos is conducting a Phase I/IIa study to evaluate the world’s first pharmaceutical endolysin as a topical therapy in humans. In Atopic Dermatitis patients, the skin microbiome is unbalanced with an over-proliferation of S. aureus, that is considered to be a causative and aggravating trigger, and viewed as an independent cause of itch, irritation and infection.
Diabetic Foot Ulcers: Infection of foot ulcers is a common, often severe complication in diabetes. S. aureus has emerged as a serious source of infections in patients with diabetic foot ulcers and is the most frequent pathogen isolated. If left untreated, severe complications can arise, including amputation.
Bloodstream Infections: S. aureus is a common cause of deadly bloodstream infections, with an increasing proportion of infections due to MRSA. This often leads to sepsis syndrome, with a high mortality rate.
Cancer: Cutaneous T-cell Lymphoma is a type of cancer of the immune system, located in the skin. It has now been discovered that S. aureus bacteria on the skin produce staphylococcal enterotoxins that stimulate the growth of malignant T-cells.
“We’re beginning to appreciate that the importance of biodiversity extends beyond the rainforest, right up to our very own bodies and wellbeing. Clinical studies demonstrate the interplay between the commensal microbiota on and inside our bodies, and our immune system, as demonstrated by the emergence and increase of many chronic diseases and even certain forms of cancer. This new paradigm requires a new approach, which we have embraced as our mission.” says Mark Offerhaus, founder and CEO of Micreos.
Micreos develops new biological therapies based on targeted killing of only unwanted bacteria, set to replace antibiotics in a wide range of applications, The company is viewed as a global leader in this field. Its proprietary endolysin technology has been created together with the Swiss Federal Technology Institute, ETH Zurich. Headquartered in The Hague, The Netherlands, Micreos runs its technology center in Zurich, with operations in the Netherlands and the USA. Under the Gladskin brand, Micreos has launched several endolysin-based OTC products for people with inflammatory skin conditions caused or aggravated by S. aureus, including acne, eczema and rosacea, and helped hundreds of thousands of people.
For more information please contact: Melanie Stinn, Head of Communications (firstname.lastname@example.org) +49-151-2126-1437
The Hague, 22 September 2020, Dutch biotech company Micreos Human Health has enrolled the first patients in a Phase I/IIa, randomized, double-blind, placebo-controlled, parallel treated dose-ranging study to assess the safety and efficacy of XZ.700 in patients with mild to moderate atopic dermatitis. The study marks the world’s first evaluation of a pharmaceutical endolysin for topical use in humans.
Endolysins are highly specific enzymes that cut the bacterial cell wall, rapidly killing only the target bacteria, regardless of antibiotic resistance, while preserving the skin microbiome. XZ.700 specifically targets Staphylococcus aureus (S. aureus), a bacterium that is considered to be a causative and aggravating trigger for atopic dermatitis, and viewed as an independent cause of itch, irritation and infection.
“The targeted removal of one particular bacterial species, S. aureus, from the skin microbiome, while preserving the beneficial ones is a fundamental new way to treat atopic dermatitis,” says dermatologist Dr. Peter Lio, Scientific Advisor for Micreos and Scientific Advisory Board member for the National Eczema Association. XZ.700 is one of several endolysins Micreos has in its portfolio. A structurally similar endolysin, SA.100, is used in the company’s over the counter (OTC) products for inflammatory skin disorders (e.g. acne and rosacea), found in the Gladskin range, which have been on the market since 2013. Data obtained in earlier Gladskin studies and feedback from doctors and thousands of customers support the pharmaceutical development program: “I am very encouraged by my experience with Gladskin and I am awaiting the findings with great anticipation.”
In this study, conducted in The Netherlands, XZ.700 will be tested for its safety as well as pharmacodynamics and efficacy in 48 patients with atopic dermatitis. They will be treated for 14 days with a cream containing XZ.700 at three different concentrations or placebo. Micreos expects to finish the study and report the results towards the end of 2021. More information about the study can be obtained at this link (www.trialregister.nl/trial/8876).
“Thanks to the targeted nature of endolysins and the fact that emergence of resistance is not expected, we can use them as effective precision tools in the post-antibiotic era, in both chronic and critical situations. With the start of the XZ.700 trial we take the technology to the next level and create tomorrow’s history.” says Mark Offerhaus, CEO Micreos.
Endolysins are cell wall degrading enzymes, derived from naturally occurring phages. XZ.700 is Micreos’ endolysin in pharmaceutical development which targets S. aureus, including the antibiotic-resistant MRSA, while preserving Staphylococcus epidermidis, considered to be beneficial on the skin and conducive to wound healing. First targeted XZ.700 indications are Atopic Dermatitis, Diabetic Wound Infections caused by S. aureus, including MRSA, and Cutaneous T-cell Lymphoma, targeting S. aureus as a possible trigger for malignancy in this form of cancer in the skin.
Micreos develops new biological therapies based on phage & endolysin technology and is considered the leader in this field. The company provides the world’s first targeted antibacterial products set to replace antibiotics. Headquartered in The Netherlands, with a central staff in The Hague, Micreos has a technology centre in Zurich, Switzerland, and three separate business units: Pharma, OTC and Food Safety with operations in the Netherlands and the USA. The company works closely together with ETH Zurich and many medical and technology centres, including Erasmus Medical Centre (Rotterdam, NL), the Public Health Lab Kennemerland (Haarlem, NL), Academic Centre for Dentistry Amsterdam (ACTA, Amsterdam, NL) and Copenhagen University (Copenhagen, DK).
Press Contact: Melanie Stinn (email@example.com): +49-151-2126-1437